SPOTLIGHT: Sonus lays off workers in restructuring

Sonus Pharmaceuticals is laying off 16 workers and stopping work on two oncology programs so it can focus its resources on its early-stage drug SN2310 while exploring in-licensing opportunities and strategic transactions. Release

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.